Eupraxia Pharmaceuticals Inc. (EPRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $6.62
- As of
Kresmion compiles this page from EPRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
EUPRAXIA PHARMACEUTICALS INC. (EPRX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-11-10.
See the full EPRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for EPRX on one page. Preview it with sample data, then open it live with a free account.
Preview the EPRX dossierActive events for EPRX
- mediumEarnings above estimates
Q3-2026: Beat consensus by 19.5%, EPS $-0.23 vs $-0.2856 estimate
- high13F: funds added
3 tracked funds increased EPRX this 2026Q2, institutional consensus
- medium13F: new position
CITADEL ADVISORS LLC new position in EPRX
- medium13F: new position
MILLENNIUM MANAGEMENT LLC new position in EPRX
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +1947% to EPRX (2026Q2)
FREE, NO ACCOUNT
Every event on EPRX, as it fires
You are seeing 5 of 9 events recorded on EPRX since 2026-05-31.
The five above landed across 3 days. The other 4 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, EPRX
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
More data on EPRX
EPRX against its peers
EPRX's return on equity of -47.0% ranks in the 52nd percentile of 21 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | EPRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 7.3M USD | 16 | 15 |
| Operating margin | n/a | -387.5% | n/a | 12 |
| Net margin | n/a | -239.0% | n/a | 12 |
| Return on equity | -47.0% | -53.8% | 52 | 21 |
| 1 year | 18.4% | 5.5% | 70 | 21 |
Peers (22): CAPR, MYGN, ZVRA, VALN, SANA, ENTX, FTH, OBIO, SRZN, CBIO, RGNX, NGNE, GERN, CLYM, MNPR, CGEM, ABUS, WVE, OVID, DMAC, STTK, DSGN. Left out: IAM (no annual filing), SLBT (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (EPRX: 40-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in EPRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on EPRX in the last 180 days.
Upstream: SEC EDGAR filings for EPRX
Kresmion, "EUPRAXIA PHARMACEUTICALS INC. (EPRX) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/EPRX. Upstream data: SEC EDGAR filings for EPRX.
Link to this data (HTML):
<a href="https://kresmion.com/research/EPRX">EUPRAXIA PHARMACEUTICALS INC. (EPRX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow EPRX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to EPRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.